Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant965 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,240 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04922047 | Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)(TACBIN-01) | unknown | Phase 1 / Phase 2 | 6 | RenJi HospitalOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT04909775 | Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04891055 | Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)(I-Rene) | unknown | — | 90 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT04878250 | Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder(PEBBLE) | unknown | Phase 2 | 49 | Queen Mary University of LondonOTHER | 0 | May 7, 2021 | clinicaltrials |
| NCT03624673 | Endoscopic Robot-Assisted Simple Enucleation Versus Standard Robot-Assisted Partial Nephrectomy in the Treatment of T1 Renal Cell Carcinoma | unknown | N/A | 380 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT02957370 | Molecular Biosensors for Detection of Bladder Cancer | unknown | — | 230 | University of California, IrvineOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT03664869 | Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer(FB10) | unknown | Phase 3 | 300 | Turku University HospitalOTHER_GOV | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04812145 | Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma | unknown | — | 50 | Assiut UniversityOTHER | 0 | Mar 23, 2021 | clinicaltrials |
| NCT04798963 | The Evaluation of Functional Parenchymal Volume and Split Renal Function Before and After Partial Nephrectomy | unknown | N/A | 60 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT03824691 | hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"(ARCADIA) | unknown | Phase 2 | 122 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT04750590 | Relationship Between Methods of Bladder Tumor Extraction and Local Recurrence Rate | unknown | N/A | 180 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04305730 | Use of Pedometer Following Radical Cystectomy | unknown | N/A | 35 | Benaroya Research InstituteOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT04756284 | Evaluation of the PhageTech Virus BioResistor | unknown | — | 50 | PhageTech, Inc.INDUSTRY | 1 | Feb 16, 2021 | clinicaltrials |
| NCT04666220 | VETC, Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Carcinoma | unknown | — | 180 | Humanitas Clinical and Research CenterOTHER | 1 | Feb 12, 2021 | clinicaltrials |
| NCT04383067 | A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | unknown | Phase 2 | 20 | Sheba Medical CenterOTHER_GOV | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04738630 | Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer | unknown | Phase 2 | 110 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04714697 | Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma | unknown | Phase 2 | 201 | Asan Medical CenterOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT03738488 | 3D-biomodels for Surgical Planning in Patients With Renal Cancer and Vascular Involvement(3DUrologia) | unknown | N/A | 10 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT04712201 | En Bloc Bladder Tumor Resection: Prospective Randomized Study | unknown | N/A | 300 | Fundacio PuigvertOTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT04702347 | Genetic Testing in Upper Tract Urothelial Carcinoma (UTUC): the Epicheck Study | unknown | — | 80 | Fundacio PuigvertOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT00507884 | Pilot Study to Develop 3 Tesla MRI for Evaluation of Renal Tumors | unknown | — | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 31, 2020 | clinicaltrials |
| NCT04687254 | Gender-related Characteristics of Bladder Cancer Treatment(BladderBLOG) | unknown | — | 500 | University of FlorenceOTHER | 1 | Dec 29, 2020 | clinicaltrials |
| NCT04686149 | a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients | unknown | — | 39 | Yonsei UniversityOTHER | 1 | Dec 28, 2020 | clinicaltrials |
| NCT04134182 | Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. | unknown | Phase 2 | 8 | Kidney Cancer Research BureauOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT04669613 | Contrast Ultrasound Dispersion Imaging (CUDI) as a Diagnostic Modality in the Diagnosis of Renal Cell Carcinoma(CUDI-RCC) | unknown | N/A | 10 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04523025 | Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR)(NorCys-NLR) | unknown | — | 230 | Turku University HospitalOTHER_GOV | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04523038 | Nordic Cystectomy Study II - Albumin(NorCys-Alb) | unknown | — | 1,700 | Turku University HospitalOTHER_GOV | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04537221 | Nordic Cystectomy Study III - Transfusion(NorCys-Transf) | unknown | — | 1,700 | Turku University HospitalOTHER_GOV | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04644432 | Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma(INDIGO) | unknown | Phase 2 | 30 | Herlev and Gentofte HospitalOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04211012 | A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma | unknown | Phase 2 | 30 | Jun GuoOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04609293 | Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma | unknown | — | 30 | Peking University First HospitalOTHER | 0 | Oct 30, 2020 | clinicaltrials |
| NCT04610385 | Ileal Conduit Versus Cutaneous Ureterostomy After Radical Cystectomy | unknown | — | 40 | Assiut UniversityOTHER | 0 | Oct 30, 2020 | clinicaltrials |
| NCT04402411 | Quadratus Lumborum Block vs Transversus Abdominis Plane Block in Bladder Cancer Surgeries | unknown | N/A | 63 | National Cancer Institute, EgyptOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04588168 | Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma | unknown | N/A | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04244136 | Residual Normal Renal Parenchymal and Tumor Volume in Tumor Surgeries | unknown | — | 32 | Assiut UniversityOTHER | 0 | Oct 8, 2020 | clinicaltrials |
| NCT03086174 | Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma | unknown | Phase 1 | 24 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT03113266 | Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma | unknown | Phase 2 | 370 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04286672 | Metadherin mRNA Expression in Bladder Cancer | unknown | — | 70 | Assiut UniversityOTHER | 0 | Sep 29, 2020 | clinicaltrials |
| NCT04424472 | Assessing the Utility of Ultrasound Compared to Cross-Sectional Imaging in the Follow-up of Patients With Renal Cell Carcinoma | unknown | N/A | 50 | University of Kansas Medical CenterOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT03226886 | TRACERx Renal CAPTURE Sub-study(TRACERxRenal) | unknown | — | 360 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT04525781 | Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer | unknown | — | 150 | Assiut UniversityOTHER | 0 | Aug 25, 2020 | clinicaltrials |
| NCT04493489 | Propranolol Adjuvant Treatment of Bladder Cancer | unknown | Phase 2 | 242 | Central South UniversityOTHER | 0 | Jul 30, 2020 | clinicaltrials |
| NCT04219046 | Evaluation of Naloxegol in the Prevention of POI After Cystectomy(ANTAGOCYST) | unknown | Phase 2 | 102 | Institut Paoli-CalmettesOTHER | 0 | Jul 28, 2020 | clinicaltrials |
| NCT04476641 | A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors(DC-CIK) | unknown | Phase 2 | 686 | Sun Yat-sen UniversityOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03254888 | Autophagy Bladder Cancer | unknown | — | 150 | Assiut UniversityOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT03987698 | Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04256616 | Immunogenic Cell Death as a Novel Mechanism of Mitomycin C Activity in Bladder Cancer(ICH-MIM-01) | unknown | — | 110 | Istituto Clinico HumanitasOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04406168 | Assessment of Urinary Diversions Outcomes Post Radical Cystectomy in Asyut University Urology Hospital | unknown | — | 40 | Assiut UniversityOTHER | 1 | May 28, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 11, 2021source: clinicaltrials